+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Approach to pseudomyxoma peritonei

Approach to pseudomyxoma peritonei

World Journal of Gastrointestinal Surgery 10(5): 49-56

Pseudomyxoma peritonei (PMP) is a mucinous tumour of the appendix that spreads into the peritoneal cavity in the form of gelatinous deposits. The incidence of PMP is believed to be approximately 1-3 out of a million per year. Nonetheless, due to its indolent nature, it is usually discovered at an advanced stage and severely impacts quality of life. Curative treatment for PMP is complete cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). An extensive literature review was conducted searching EMBASE, MEDLINE, PubMed, and Google Scholar databases for PMP in aims to delineate a clinical approach to diagnosis and treatment. Literature was limited to the years 2007-2018. We found the 5-year overall survival with CRS and HIPEC estimated to be between 23%-82% and rates of major complications as high as 24%. Therefore, it is important to appropriately stage and select patients that should undergo CRS with HIPEC. Modalities like MDCT radiological scores have been shown to have sensitivity and specificity of 94% and 81%, respectively, in being able to predict resectability and survival. Despite treatment, the disease often recurs. Tumor markers have significant potential for establishing prognosis pre-operatively, and this paper will review the most recent evidence in support of them.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 065697605

Download citation: RISBibTeXText

PMID: 30190782

DOI: 10.4240/wjgs.v10.i5.49

Related references

Pseudomyxoma peritonei--a palliative approach. Palliative Medicine 13(5): 444, 1999

Curative approach to pseudomyxoma peritonei. Contemporary Surgery 38(4): 13-21, 1991

Pseudomyxoma peritonei - a palliative approach. Palliative Medicine 13(5): 444-444, 1999

Preserving fertility in pseudomyxoma peritonei, a novel approach. Pleura and Peritoneum 2(1): 33-36, 2017

Pseudomyxoma peritonei: new concept and new therapeutic approach. Annales de Chirurgie 130(2): 63-69, 2005

Extensive peritonectomy. A new treatment approach to pseudomyxoma peritonei. Ugeskrift for Laeger 166(35): 2981-2984, 2004

Peritoneoscopic appearance of pseudomyxoma peritonei a diagnostical approach by peritoneoscopy. Endoscopy 7(3): 176-179, 1975

Pseudomyxoma peritonei (mucinous carcinoma peritonei) preceded by intraductal papillary neoplasm of the bile duct. Human Pathology 43(7): 1148-1152, 2012

An evidence-based approach: Sugarbaker protocol and pseudomyxoma peritonei of appendiceal origin. Anz Journal of Surgery 78(5): 327-328, 2008

Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Annals of Surgery 219(2): 112-119, 1994

Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Tumori 87(4): S3-S5, 2001

Malignant pseudomyxoma peritonei of colonic origin. Natural history and presentation of a curative approach to treatment. Diseases of the Colon and Rectum 30(10): 772-779, 1987

Cytoreductive surgery (peritonectomy) and intraperitoneal hyperthermic chemotherapy: an innovative and effective approach to the treatment of pseudomyxoma peritonei. Tumori 89(4 Suppl): 54-55, 2003

Laparoscopic approach in complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy by CO 2 closed system in a low grade pseudomyxoma peritonei. Cirugia Espanola 96(10): 656-658, 2018

Appendiceal mucoceles, pseudomyxoma peritonei and appendiceal mucinous neoplasms: update on the contribution of imaging to choice of surgical approach. Journal de Chirurgie 146(2): 150-166, 2009